Factor viia for alveolar hemorrhage in microscopic polyangiitis

Betensley, Alan D.; Yankaskas, James R.

doi:10.1164/ajrccm.166.9.267d

Cited by 39 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are case reports and a proposal to use recombinant coagulation factor VIIa as a prothrombotic or hemostatic agent. 11 Owing to its cost and its potential association with systemic thrombosis it has not been well studied in the transplant population. Currently, a randomized, placebo-controlled study of recombinant VIIa is being evaluated in the treatment of hemorrhage in marrow transplant recipients.…”

mentioning

confidence: 99%

Diffuse alveolar hemorrhage: an evolving problem?

Weisdorf

2003

Leukemia

View full text Add to dashboard Cite

mentioning

confidence: 99%

Diffuse alveolar hemorrhage: an evolving problem?

Weisdorf

2003

Leukemia

View full text Add to dashboard Cite

“…Several reports have focused on the successful use of rFVIIa to control diffuse pulmonary hemorrhage in non-injured patients with autoimmune disorders and after hematopoietic stem-cell transplantation [12][13][14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

Treatment of Diffuse Pulmonary Hemorrhage with Factor VIIa

Schreiber

Lautenschlaeger

Breuer

et al. 2008

Eur J Trauma Emerg Surg

View full text Add to dashboard Cite

Blunt thoracic trauma resulting in lung contusion with severe diffuse pulmonary hemorrhage and massive hemoptysis is rare and has a poor prognosis. Treatment options are limited. We report a case of the successful use of recombinant activated factor VII (NovoSeven™) in the treatment of life-threatening diffuse pulmonary hemorrhage secondary to an isolated blunt force thoracic injury without relevant traumatic coagulopathy.

show abstract

“…For the scenario of DAH, consideration should be given to the risk of further bleeding with plasma exchange due to loss of coagulation factors and the risk of transfusionrelated acute lung injury associated with administering blood products during the exchange. Other potential therapies for DAH include extracorporpeal membrane oxygenation and activated human factor VII, though studies of these treatment methods are limited to case reports [Ahmed et al 2004;Matsumoto et al 2000;Betensley and Yankaskas, 2002;Dabar et al 2011;Henke et al 2004].…”

Section: Remission Inductionmentioning

confidence: 99%

Diagnosis and management of pulmonary vasculitis

Yunt

Frankel

Brown

2012

Ther Adv Respir Dis

View full text Add to dashboard Cite

Abstract:The pulmonary vasculitides are a heterogeneous group of disorders characterized pathologically by vascular destruction with cellular inflammation and necrosis. These disorders can affect small, medium, and large vessels and may be primary or occur secondary to a variety of conditions. Vasculitis involving the lungs is most commonly due to primary, idiopathic, small-vessel antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, which includes granulomatosis with polyangiitis (formerly Wegener's granulomatosis), ChurgStrauss syndrome, and microscopic polyangiitis. From a clinical perspective these remain among the most challenging of diseases both in terms of diagnosis and treatment. This review will focus on diagnosis and management of ANCA-associated vasculitides.

show abstract

Factor viia for alveolar hemorrhage in microscopic polyangiitis

Cited by 39 publications

References 9 publications

Diffuse alveolar hemorrhage: an evolving problem?

Diffuse alveolar hemorrhage: an evolving problem?

Treatment of Diffuse Pulmonary Hemorrhage with Factor VIIa

Diagnosis and management of pulmonary vasculitis

Contact Info

Product

Resources

About